Basal proteinuria as a prognostic factor in patients with metastatic colorectal cancer treated with bevacizumab

Uysal, Mukremin; Bozcuk, Hakan; Göksu, SEMA; Tatlı, ALİ; Arslan, Deniz; Gunduz, ŞEYDA; COŞKUN, HASAN; Özdoğan, Mustafa; Savaş, Burhan

doi:10.1016/j.biopha.2014.03.002

Basal proteinuria as a prognostic factor in patients with metastatic colorectal cancer treated with bevacizumab

Copy For Citation

Uysal M., Bozcuk H., Göksu S. S., Tatlı A. M., Arslan D., Gunduz S., ...More

BIOMEDICINE & PHARMACOTHERAPY, vol.68, no.4, pp.409-412, 2014 (SCI-Expanded)

Publication Type: Article / Article
Volume: 68 Issue: 4
Publication Date: 2014
Doi Number: 10.1016/j.biopha.2014.03.002
Journal Name: BIOMEDICINE & PHARMACOTHERAPY
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.409-412
Keywords: Bevacizumab, Metastatic colorectal cancer, Prognostic and predictive factors, Proteinuria, PREOPERATIVE CARCINOEMBRYONIC ANTIGEN, FLUOROURACIL, LEUCOVORIN, HYPERTENSION, IRINOTECAN, OUTCOMES
Akdeniz University Affiliated: Yes

Abstract

Background: The beneficial effects of bevacizumab, a widely used agent in metastatic colorectal cancer (mCRC), on clinical survival have been proven. This study investigated the correlation of the clinical benefits and prognosis with proteinuria and other parameters.